कृपया अन्य खोज का प्रयास करें
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Peter Hendricks | - | 2022 | Member of Scientific Advisory Board |
Ian McDonald | 34 | 2019 | Co-Founder, CEO, President & Director |
Jeremy Fryzuk | 38 | 2020 | Independent Director |
Michael P. Bogenschutz | - | 2022 | Member of Scientific Advisory Board |
Jan Torleif Pedersen | 58 | 2022 | Chief Science Officer & Director |
Robert C. Malenka | - | 2022 | Member of Scientific Advisory Board |
Nils Christian Bottler | 36 | 2020 | Independent Director |
Herbert Y. Meltzer | - | 2022 | Member of Scientific Advisory Board |
David M. Weiner | 59 | 2023 | Independent Non-Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है